Table 5.

Relative expression of mRNA levels in tumor samples after ex vivo exposure to doxorubicin. The IC₅₀ concentrations for the samples tested are shown for each drug (median and range). The p values have been calculated using non-parametric statistics, in detail the Wilcoxon matched pairs test. On statistical advice, we chose not to use a Bonferroni's correction, but it should be noted that some technically statistically significant results could have arisen by chance.

	Breast samples				Ovarian samples
Target gene	n	Control	Doxorubicin IC50 = 0.828 μM (0.569–1.16)	p	n	Control	Doxorubicin IC50 = 1.34 μM (0.310–17.7)	p
BCRP	14	0.039	0.044	0.8077	12	0.010	0.027	0.042
ERCC1	14	0.711	0.826	0.2412	11	0.440	0.506	0.4922
MDR1	14	0.069	0.056	0.0494	12	0.005	0.005	0.2036
MRP1	14	3.886	5.692	<0.0001	12	1.890	2.321	0.083
MVP	14	4.990	6.925	0.0023	12	2.251	2.687	0.042
TOPO I	14	5.464	5.128	0.0419	12	6.112	3.360	0.001
TOPO IIα	14	0.546	0.017	<0.0001	12	1.491	0.089	0.0015
TOPO IIβ	14	6.617	6.461	0.0785	12	5.907	5.252	0.0322